Evidence map›Paper›PMID 34947519›Full record

ArticleNanomaterials (Basel, Switzerland)2021

Impact of Carbon Fluoroxide Nanoparticles on Cell Proliferation.

Alain Géloën, Gauhar Mussabek, Alexander Kharin, Tetiana Serdiuk, Sergei A Alekseev, Vladimir Lysenko

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Evaluating the Use of TiOInternational journal of nanomedicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alain GéloënUMR Ecologie Microbienne Lyon (LEM), CNRS 5557, INRAE 1418, VetAgro Sup, Research Team "Bacterial Opportunistic Pathogens and Environment" (BPOE), Université Claude Bernard Lyon 1, 69622 Villeurbanne, France.
Gauhar MussabekFaculty of Physics and Technology, Al-Farabi Kazakh National University, 71, al-Farabi Ave., Almaty 050040, Kazakhstan.
Alexander KharinUMR Ecologie Microbienne Lyon (LEM), CNRS 5557, INRAE 1418, VetAgro Sup, Research Team "Bacterial Opportunistic Pathogens and Environment" (BPOE), Université Claude Bernard Lyon 1, 69622 Villeurbanne, France.
Tetiana SerdiukUMR Ecologie Microbienne Lyon (LEM), CNRS 5557, INRAE 1418, VetAgro Sup, Research Team "Bacterial Opportunistic Pathogens and Environment" (BPOE), Université Claude Bernard Lyon 1, 69622 Villeurbanne, France.
Sergei A AlekseevChemistry Department, Taras Shevchenko National University of Kyiv, Volodymyrska Street, 64, 01601 Kyiv, Ukraine.
Vladimir LysenkoInstitute of Engineering Physics for Biomedicine, Laboratory "Bionanophotonics", National Research Nuclear University "MEPhI", Kashirskoe sh. 31, 115409 Moscow, Russia.ORCID 0000-0003-1076-7064

Funding

European Community, Program H2020-MSCA-RISE-2015 690945Ministry of Education and Science of the Republic of Kazakhstan AP08856579North Atlantic Treaty Organization SPS984702
6 · The paper itself

Abstract

Cytotoxicity of fluorescent carbon fluoroxide (CFO) nanoparticles (NPs) was studied in a label-free manner on several cancer and non-cancer cell lines. A direct cytotoxic effect of the CFO NPs was clearly observed by a suppression of cell proliferation. The real-time measurement of cell activities allowed to quantify the impact of the uptaken NPs on cell proliferation and after washout of the NPs from the cell culture medium. The results show more toxic effects of the CFO NPs on cancer than on non-cancer cell lines. The notion of NPs biocompatibility must be related to a maximum concentration value of the NPs acceptable for a given cell type. Furthermore, the cytotoxicity effects of NPs should be studied not only during their direct exposure to cells but also after their washout from the culture medium.

Indexed as

cancer cellcellular uptakecytotoxicitynanoparticlesxCELLigence

Identifiers

PMID34947519
PMCPMC8708860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.